Thomas Jefferson University

Thomas Jefferson University, operating as Sidney Kimmel Medical College and its subsidiaries, is a private non-profit academic medical center and research institution headquartered in Philadelphia, Pennsylvania, that acts as a prime recipient of federal research grants and a subrecipient on grant-funded research conducted across academic and clinical partners. The institution competes across full-and-open federal funding mechanisms, with no small-business set-asides reported, and operates a substantial research enterprise centered on biomedical research, medical education, and clinical services.

Thomas Jefferson University's federal award footprint is dominated by investigator-initiated research grants from the National Institutes of Health and specialized research-performing contracts with the Department of Defense and Department of Veterans Affairs. The institution receives federal funding for basic and translational cancer research, neurobiology (particularly neurodegeneration and neuroimmunology), infectious disease research, and cardiovascular research through an active portfolio spanning approximately 1,593 awards across all federal sources. Recent representative prime grant work includes a $1.998 million Defense Health Agency award to support research deciphering PIK3CA mutations in tumorigenesis of HER2-positive breast cancer (CFDA 12.420, performance through August 31, 2029); a $712,776 National Institute of Allergy and Infectious Diseases grant investigating the role of solute carrier 15A4 in antimicrobial inflammatory responses and autophagy in dendritic cells (CFDA 93.855, through July 31, 2031); and a $651,545 National Cancer Institute award to develop and evaluate CONNECT, a multilevel intervention combining electronic monitoring, navigator-led self-management education, and social prescribing to improve endocrine therapy adherence in women with hormone receptor-positive breast cancer (CFDA 93.395, through July 31, 2031). Contract work includes a $55,000 purchase order from the National Institute of Diabetes and Digestive and Kidney Diseases for clinical cohorts with dataset and associated imaging to support AI-based research on liver cancer risk (awarded September 28, 2026, completion September 27, 2028); medical education delivery contracts with the Bureau of Medicine and Surgery, Department of the Navy, and Veterans Integrated Service Network 4 for tuition and fees supporting military medical education; and affiliate clinical services contracts for dermatology and other specialty care delivered through institutional clinical networks.

Customer concentration reflects the NIH's dominance in the institution's federal portfolio. The Department of Health and Human Services National Institutes of Health accounts for 389 awards (approximately 24% of total prime awards by count), with the National Cancer Institute placing 158 awards and the National Institute of Allergy and Infectious Diseases 88 awards. By combined potential value, the National Institute of Allergy and Infectious Diseases leads at $27 million, followed by the Veterans Integrated Service Network 4 at $7.8 million and the Department of the Navy's Bureau of Medicine and Surgery at $6.9 million. Top NIH entities by award count include the National Cancer Institute, National Institute of Neurological Disorders and Stroke (75 awards), National Heart, Lung, and Blood Institute (74 awards), and National Institute of General Medical Sciences (63 awards). Veterans Affairs and Department of Defense (Military Medical Research and Development) funding reflects the institution's participation in military medical education and translational oncology research relevant to service member health.

Parent contract vehicles are limited and reflect the institution's positioning primarily as a direct grantee rather than a task-order performer on government-wide acquisition contracts. The largest parent vehicle in SCI-derived records is an Indefinite Delivery Contract (N0014098G2462, Navy) with 76 task orders and $7 million in combined potential value; a Basic Ordering Agreement (N0060085G1731, Navy) carries 23 task orders; and another Basic Ordering Agreement (F3360075A0542, Air Force) holds 10 task orders. The institution does not appear on major civilian GWACs (such as OASIS or Alliant) in the disclosed source data; its federal work operates primarily through direct award mechanisms, grant mechanisms, and subordinate task-order activity under Navy and Air Force research vehicles.

Activity has grown modestly over the past five years—77 awards in 2023, 130 in 2024, 79 in 2025, and 85 in 2026—with 123 awards (combined potential value $27.7 million) approaching completion within the next twenty-four months, representing substantial recompete and pipeline activity. SCI-reported invoiced revenue totaled $11.5 million in FY2022 but dropped to zero in FY2023–FY2025, reflecting the institution's positioning outside heavily SCI-reportable service-contract categories; the institution's federal revenue derives predominantly from grants, not federally reportable service contracts above the $150,000 threshold. SCI-derived FTE data indicates minimal direct labor reporting (0.6–1.2 FTEs across a four-year span), consistent with an academic research institution where the majority of effort is delivered by faculty investigators, postdoctoral researchers, and graduate students whose labor is not separately line-itemized in SCI records.

Corporate structure includes four named subsidiaries: Jefferson Health Corporation, Kennedy Health System, Inc., Albert Einstein Medical Center, and Philadelphia University, which collectively reflect the institution's integration of clinical delivery, hospital operations, and educational programming. The institution houses the Sidney Kimmel Cancer Center, an NCI-designated comprehensive cancer center with established research infrastructure in cancer biology, translational medicine, immunology, and clinical trials. Recent grant awards also surface research focus in neurodegenerative disease (particularly ALS, Alzheimer's disease, and frontotemporal dementia), infectious disease vectorology (anti-tick and anti-rabies vaccine development), and women's health (maternal-fetal medicine, breast cancer, ovarian cancer, and perinatal care).

Thomas Jefferson University operates as a research-intensive academic medical institution with a hybrid footprint: it functions as a direct recipient of NIH research grants, a prime contractor for Department of Defense military medical research, and a clinical education provider to military and federal healthcare systems. The institution does not compete predominantly under small-business set-asides or on government-wide acquisition vehicles; instead, it leverages its research and clinical infrastructure to compete for competitive research funding and clinical services contracts. The recompete cliff of $27.7 million in potential value over the next twenty-four months signals active renewal and competition pipeline activity across NIH, DoD, and VA funding streams.